
111, Inc.
YINASDAQHealthcareMedical - Distribution
前收盤價
US$3.53
−US$0.03 · -0.84%
盤後
US$3.81
+US$0.28 · +7.93%
8月24日 下午7:30 ET
YI公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Sell
Trim exposure — unfavorable risk-reward
估值
35
Expensive
動能
26
Weakening
情緒
57
Mixed
風險韌性
32
High Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
- 產業
- Medical - Distribution
- 部門
- Healthcare
- 總部
- CN
- 執行長
- Junling Liu
- 上市以來
- 2018年9月12日
- 僱員
- 1,063
市場位置
日內區間
目前US$3.53,
52週區間
目前US$3.53,
- 開盤價
- US$3.68
- 前收盤價
- US$3.56
- 成交量
- 1803
- 0.1× 平均值
- 平均成交量
- 1.79萬
- 日均成交量
- 市值
- 3083.83萬 USD
- 貝塔
- 0.67
- 市場參考 1
- 50天平均值
- US$3.9256
- 低於平均水平-10.08%
- 200天平均值
- US$5.1337
- 低於平均水平-31.24%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- -1.88億 CNY
- 本益比(TTM)
- -2.43×
- 股價淨值比(TTM)
- -1.95×
- 股價營收比(TTM)
- 0.02×
- EV/EBITDA
- -103.85×
- 盈餘收益率
- -10.81%
- 自由現金流收益率
- 73.63%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 5.74%
- 營業利益率
- -0.24%
- 淨利潤率
- -0.66%
- 股東權益報酬率
- 2.40%
- 資產報酬率
- -0.77%
- 投入資本報酬率
- -2.31%
財務健康
- 負債權益比
- -0.38×
- 流動比率
- 1.09×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(CNY) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 122.14億 CNY | 144.01億 CNY | 149.48億 CNY | 135.17億 CNY | 124.26億 CNY |
| 銷貨成本 | 115.1億 CNY | 135.72億 CNY | 140.99億 CNY | 126.77億 CNY | 118.05億 CNY |
| 毛利 | 7.04億 CNY | 8.29億 CNY | 8.49億 CNY | 8.4億 CNY | 6.21億 CNY |
| 銷售、一般及管理費用 | 6.55億 CNY | 3.85億 CNY | 6.73億 CNY | 6.64億 CNY | 7.2億 CNY |
| 營業費用 | 7.14億 CNY | 8.27億 CNY | 11.99億 CNY | 12.11億 CNY | 12.63億 CNY |
| 利息收入 | 377.92萬 CNY | 704.1萬 CNY | 883.4萬 CNY | 811.8萬 CNY | 977.6萬 CNY |
| 利息支出 | 3460.28萬 CNY | 2833.1萬 CNY | 2014.1萬 CNY | 1344.3萬 CNY | 548.8萬 CNY |
| 折舊和攤銷 | 1184萬 CNY | 1696.7萬 CNY | 2178萬 CNY | 4081.9萬 CNY | 2722.1萬 CNY |
| 營業利益 | −1002.81萬 CNY | 211.4萬 CNY | −3.5億 CNY | −3.71億 CNY | −6.42億 CNY |
| 淨利 | −1684.33萬 CNY | −6474.3萬 CNY | −3.93億 CNY | −4.17億 CNY | −6.7億 CNY |
公司資料更新於 2026年8月25日。
財報歷史與展望
- 最新每股收益結果
- -0.6
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
YI 訊息
YI同業公司
繼續GoAI的研究
在 GoAI 中研究YIresearch.disclaimer







